ReviewMolecular neurobiology2025
Exploring the Immunomodulatory Role of Forkhead Box Protein 3 (FOXP3) in the Pathophysiology of Neuropsychiatric Disorders.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropsychiatric disorders represent a diverse range of conditions, such as schizophrenia, major depressive disorder (MDD), anxiety, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD), with shared immunological and neuroinflammatory signatures. The key immunomodulatory role of forkhead box P3 (FoxP3), the master transcription factor for developing and maintaining regulatory T cells (Tregs), has been highlighted in recent research in central nervous system (CNS) diseases. This review integrates evidence of FoxP3 expression and dysregulation correlating with the development and evolution of neuropsychiatric disorders. We discuss FoxP3's molecular architecture, physiological roles, and its growing role in controlling neuroinflammation and immune homeostasis. We discuss further the complex network of signaling pathways-JAK-STAT, IL-2/STAT5, TGF-β/SMAD, PI3K/Akt/mTOR, AMPK, NF-κB, and Notch-controlling or controlled by FoxP3 based on both preclinical and clinical evidence. It is suggested by research that modulation of these pathways impairs FoxP3 expression and Treg function, thus modifying neuroimmune homeostasis and neuropsychiatric outcome. The interaction of FoxP3 with STAT5 or SMAD3, for example, increases the suppressive potential of Treg, whereas PI3K/Akt or Notch signaling-dependent suppression of FoxP3 helps in immune deregulation. Inclusion of FoxP3 into the neuroimmune model provides an attractive paradigm through which to consider and therapeutically address immune dysfunction in neuropsychiatric illnesses. This review identifies FoxP3 as a likely biomarker and therapeutic target, opening the way for novel immunomodulatory approaches for the treatment of these incapacitating diseases.
Indexed as
Identifiers
41269385What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.